Patents by Inventor Carl Wild

Carl Wild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antiretroviral combination therapy
    Publication number: 20080039428
    Abstract: The present invention provides combinations comprising a viral maturation inhibitor and another therapeutically effective pharmaceutical agent. The invention is also directed to methods of treating a viral infection by administering such combinations.
    Type: Application
    Filed: June 29, 2007
    Publication date: February 14, 2008
    Applicant: Panacos Pharmaceuticals, Inc.
    Inventors: Graham Allaway, Nicole Kilgore, Carl Wild
  • Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
    Publication number: 20070202127
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Application
    Filed: September 28, 2006
    Publication date: August 30, 2007
    Inventors: Dani Bolognesi, Thomas Matthews, Carl Wild, Shawn Barney, Dennis Lambert, Stephen Petteway, Alphonse Langlois
  • Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
    Publication number: 20070037141
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Application
    Filed: December 17, 2003
    Publication date: February 15, 2007
    Inventors: Darii Bolognesi, Thomas Matthews, Carl Wild, Shawn Barney, Dennis Lambert, Stephen Petteway, Alphonse Langlois
  • Novel betulin derivatives, preparation thereof and use thereof
    Publication number: 20060205697
    Abstract: The present invention relates to novel synthetic derivatives of betulin and the use of such derivatives as pharmaceuticals. The present invention is directed to novel compounds of Formula I: or a pharmaceutically acceptable salt or prodrug thereof.
    Type: Application
    Filed: November 14, 2005
    Publication date: September 14, 2006
    Inventors: Gary Robinson, Carl Wild, Mark Ashton, Russell Thomas, Christian Montalbetti, Thomas Coulter, Filippo Magaraci, Robert Townsend, Theodore Nitz
  • Novel triterpene derivatives, preparation thereof and use thereof
    Publication number: 20050148561
    Abstract: The present invention relates to novel synthetic derivatives of triterpenes and the use of such derivatives as pharmaceuticals. The present invention is directed to novel compounds of Formula I: or pharmaceutically acceptable salt or ester thereof, wherein R1 is a carboxyalkanoyl, where the alkanoyl chain can be interrupted by a nitrogen, sulfur or oxygen atom, or combinations thereof.
    Type: Application
    Filed: September 27, 2004
    Publication date: July 7, 2005
    Applicant: Panacos Pharmaceuticals, Inc.
    Inventors: Carl Wild, Gary Robinson, Mark Ashton, Russell Thomas
  • Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
    Publication number: 20050020548
    Abstract: Betulin and dihydrobetulin acyl derivatives according to the present invention have been found to have potent anti-HIV activity. The compounds of the present invention have Formula I as described herein, or pharmaceutically acceptable salts thereof; wherein R1 is a C2-C20 substituted or unsubstituted carboxyacyl or ester thereof; R2 is hydrogen, halogen, hydroxyl or —OR3, R3 is C2-C20 substituted or unsubstituted carboxyacyl; and R4 is hydrogen or C(C6H5)3; wherein the dashed line represents an optional double bond between C20 and C29.
    Type: Application
    Filed: June 18, 2004
    Publication date: January 27, 2005
    Applicants: Panacos Pharmaceuticals, Inc., The University of North Carolina at Chapel Hill, Niigata University of Pharmacy and Applied Life Sciences
    Inventors: Graham Allaway, Carl Wild, Yoshiki Kashiwada, Kuo-Hsiung Lee
  • Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
    Publication number: 20050015039
    Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme.
    Type: Application
    Filed: May 24, 2004
    Publication date: January 20, 2005
    Inventors: Karl Salzwedel, Feng Li, Carl Wild, Graham Allaway, Eric Freed